Targets › EGLN3
4 programs from 4 companies in 8 trials: 3 Phase 3, 2 Phase 4, 2 Phase 1, 1 Phase 2; Genitourinary, Hematology, Psychiatry; next expected readout Oct 2027.
Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as PKM, TELO2, ATF4, GPX4 and HIF1A. Target proteins are preferentially recognized via a LXXLAP motif. Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. (UniProt, Q9H6Z9)
Open in Phaseline: the race on EGLN3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zydus Lifesciences | Desidustat PHD inhibitor | EGLN1, EGLN2, EGLN3 | Phase 4 | Chronic Kidney Diseases | – |
| Astellas | Roxadustat Hypoxia-inducible factor prolyl hydroxylase inhibitor | EGLN2, P4HTM, EGLN1, EGLN3 | Phase 3 | Chronic Kidney Disease; Dialysis; Complications; Perioperative Anemia; Kidney Failure, Chronic … | Oct 2027 |
| USRC Kidney Research | Vadadustat Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor | EGLN1, EGLN3, EGLN2 | Phase 3 | Anemia of Chronic Kidney Disease | – |
| Paul Potnuru | Vadadustat Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor | EGLN1, EGLN3, EGLN2 | Phase 2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | May 2031 |
Chronic Kidney Disease (1) Dialysis; Complications (1) Perioperative Anemia (1) Kidney Failure, Chronic (1) Kidney Failure,Chronic (1) Anemia of Chronic Kidney Disease (1) Chronic Kidney Diseases (1) Nonintubated Acute Respiratory Distress Syndrome (ARDS) (1)
small molecule (3), mixed (1)
Astellas (1) USRC Kidney Research (1) Zydus Lifesciences (1) Paul Potnuru (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.